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THERE IS EVIDENCE from animal experiments that gad- 
olinium chelates can be associated with vacuolization of 
prordmal tubular cells and increased excretion of urinary 
enzymes, suggesting the possibility of damage to the 
nephron (1.2). Clinical experience with gadolinium che- 
Iates, however, has shown them to be free of obsenrable 
human nephrotoxicity (3-131. As a result, gadolinium-en- 
hanced magnetic resonance imaging (MRI) is increasingly 
substituted for iodinated contrast examinations in pa- 
tients at risk for iodinated contrast-induced nephrotox- 
icity. Many of these human toxicity studies have been 
conducted on normal volunteers, on patients with normal 
renal function, and at low doses. But gadolinium chelates 
are now being used in seriously ill patients, in patients 
with renal insufficiency (14), and at larger and larger 
doses ( 15.16). These trends might be expected to unmask 
any intrinsic nephrotoxicity of these gadolinium chelates. 
In addition. there has been no direct comparison of gad- 
olinium and iodinated contrast to demonstrate with sta- 
tistical significance that gadolinium really is less nephro- 
toxic than iodinated contrast. 
The goal of this study was to determine if gadolinium 
chelates are significantly less nephrotoxic than iodinated 
contrast at high doses in the patient population in whom 
they are routinely used. 
METHODS 
Medical records of 342 consecutive patients at Massa- 
chusetts General Hospital (July 1992 to June 1993) and 
the University of Michigan Hospitals (September 1993 to 
January 19951 who underwent aortic, pelvic, or renal ar- 
tery magnetic resonance (MR) angiography with high- 
dose gadolinium (.2 to .4 mmol/kgl were reviewed 
retrospectively to identify patients who may have had 
contrast-induced renal failure. Patients included 190 
males and 152 females, ranging in age from 4 to 87 years, 
with a mean age of 62 years, Eighty-six of the 342 pa- 
tients (25%) had documented baseline renal insuffi- 
ciency, with a serum creatinine level > 1.5 mg/dL. primary 
indications for the MR examinations included hyperten- 
sion, renal insufficiency, abdominal aortic aneurysm, 
and peripheral vascular disease. 
AU patient medical records were reviewed to identify se- 
rum creaUnine levels pre- and postadministration of gad- 
olinium contrast. patients who did not have serum 
creatinine data within 2 days before and 2 days post- 
gadolinium were excluded from further analysis. The 
change in serum creatinlne level with gadolinium was 
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Effect of High-Dose Gadolinium on Serum Creatinine 
Table 1 
Serum Creatinine (mg/dL) 
Mean f SD (Minimum-Maximum) No. of Patients No. of Patients with Serum 
Gadolinium Chelate Reviewed Creatinine Data Pre Post Delta 
Gadopentetate 92 37 (52)* 2.44 f 1.55 2.33 2 1.46 -.11 
dimeglumine (.7-6.4) (.7-5.7) (- .7 - .4) t 
2.09 f 1.62 2.04 f 1.54 - .05 Gadodiamide 213 67 (82); 
(.5-7.1) (.6-7.01 f- .7- .41 t 
Gadoteridol 
. .  
37 6 (9); 1.78 ? .46 1.81 ? .47 .03 
( 1.2 -2.5) ( 1.2 - 2.6) (-.l-.l)t 
Total 342 110 (143). 2.20 t 1.56 2.13 f 1.48 - .07 
(.5-7.1) (.6-7.0) (- .7 - .4) t 
Includes patients on dialysis (4). patients who received gadolinium and iodinated contrast on the same day (10). and patients with 
rising serum creatinine at the time of MR angiography caused by recent aortic surgery (5), iodinated contrast-induced renal failure 
(7). hypotension or dehydration (6). or renal transplant rejection (1). 
t Values in parentheses are maximum decrease and maximum increase. 
calculated by subtracting the pregadolinium serum cre- 
atinine from the first postgadolinium serum creatinine. If 
the serum creatinine level began rising within 2 days af- 
ter the gadolinium administration, then the peak level at- 
tained during the 7 days postgadolinium was considered 
to be the post-gadolinium creatinine level for purposes of 
calculating the change in serum creatinine. The type and 
dose of gadolinium used for each patient were recorded. 
Medical records were also reviewed to identify the date 
of any study in which each of these patients may have 
also received iodinated contrast, including cardiac cath- 
eterization, angiography, intravenous pyelography, or 
contrast-enhanced computed tomography (CTJ. Data on 
serum creatinine levels within 2 days pre- and post- 
iodinated contrast were also reviewed, and the change in 
serum creatinine after iodinated contrast was calculated 
in exactly the same manner as used with the gadolinium 
contrast. 
Data from patients who received gadolinium and iodi- 
nated contrast within a 48-hour interval were included 
only if serum creatinine data were available in between 
the two studies (eight patients). Data from patients who 
received gadolinium and iodinated contrast on the same 
day (10 patients) or who were on dialysis (4 patients) were 
excluded. Data from patients whose renal function was 
unstable at the time of imaging were also excluded (19 
patients). These included five patients who were unstable 
postaortic surgery, seven patients with iodinated con- 
trast-induced renal failure at the time of MRI, six patients 
with hypotensionldehydration, and one patient subse- 
quently shown to have renal transplant rejection. 
Patients who received iodinated contrast received a va- 
riety of types of both ionic and nonionic iodinated con- 
trast, including sodium diatrizoate (hypaque), meglumine 
iothalamate (conray), sodium/meglumine diatrizoate 
(renografin), sodium/meglumine ioxaglate (hexabrix), io- 
hexol (omnipaque), and iopamidol (isovue). Many pa- 
tients received more than one type of iodinated contrast 
during a single examination. The choice of iodinated con- 
trast agent (ionic versus nonionic) was based partly on 
the goal of maximizing patient safety and partly on the 
personal preference of the radiologist or cardiologist do- 
ing the procedure. The typical iodinated contrast doses 
were 60 g of iodine for an aortogram and runoff, 30 g of 
iodine for a renal arteriogram, 40 to 50 g of iodine for CT 
scans, and 50 g of iodine for a cardiac catheterization 
examination. The exact dose of iodinated contrast used 
for each patient was not documented in sufficient detail 
to allow stratification of the data into different iodinated 
contrast doses. 
The three types of gadolinium chelates used included 
gadopentetate dimeglumine (Magnevist , Berlex Labora- 
tories, Wayne, NJ), gadodiamide (Omniscan, Nycomed, 
Princeton, NJ),  and gadoteridol (ProHance, Bracco, 
Princeton, NJ) .  The choice of gadolinium contrast agent 
was based on the compound in stock at the time of im- 
aging and was not made on the basis of any patient char- 
acteristics. Gadolinium was administered in combination 
with a saline flush in all cases and in most cases in com- 
bination with 150 to 250 ml of fluid via an intravenous 
line. 
Statistical Analysis 
The significance of changes in serum creatinine after 
gadolinium contrast and iodinated contrast was calcu- 
lated with Student's t test for paired data. Student's t test 
for paired data was also used to determine if the mean 
change in serum creatinine with gadolinium was signifi- 
cantly different than the mean change in serum creati- 
nine with iodinated contrast. This statistical analysis was 
then repeated for the subgroup of patients who had renal 
insufficiency. It was repeated for the subgroups of pa- 
tients corresponding to those who received each of the 
three different gadolinium chelates. All calculations were 
performed on a computer (Macintosh Quadra 700, Apple 
Computer, Cupertino, CA) using a spreadsheet program 
(Excel Version 4.0, Microsoft, Seattle, WA). 
RESULTS 
Review of 342 patients who received high-dose gadolin- 
ium (.2 to .4 mmol/kg) identified 143 patients who had 
serum creatinine data within 2 days pre- and postgado- 
linium. Thirty-three of these patients were excluded be- 
cause of confounding variables (see Methods and Table 
--1 Table 2 Effect of Gadolinium Dose on Changes in Serum Creatinine Serum Creatinine 
(mg/dL) 
Mean f SD 
Gado- No. (Minimum- Maximum) linium of 
Dose Patients Pre Post Delta 
I .2-.29 73 2.23 ? 1.62 2.19 f 1.56 -.04 I (.5-7.1) (.6-7.0) (-.7-.4)* 
I .3-.40 37 2.01 f 1.28 1.96 f 1.20 -.05 t.7-6.2) I.7-6.11 (-.7-.4)* *Values in parentheses are maximum decrease and maxi- 
I mum increase. I 
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Table 3 ~___. - 
Changes in Serum Creatinine Gadolinium Chelates Versus Iodinated Contrast Agents 
Serum Creatinine ImddL1 
Mean t SD 
Delta No. of (Minimum-Maximum) 














2.33 t 1.54 
[. 7 - 5.7) 
[.8 - 4.7) 
2.01 ? 1.06 
2.21 f 1.77 
2.01 ? 1.67 
1.78 t .46 





2.21 t 1.60 
1.99 f 1.41 
(.6- 7.1) 
(.6-7.1) 
2.26 t 1.47 
(. 7 - 5.4) 
2.66 k 2.03 
(.8-7.8) 
2.12 2 1.68 
f.7-7.01 
2.22 c 1.’79 
(.7-7.1) 
1.81 f .47 
1.97 2 .51 
( 1.2 - 2.6) 
(1.2-2.7) 
2.14 t 1.53 
(.7-7.0) 
(. 7 - 7.8) 
2.34 t 1.80 
-.07 






(- .3 - 2.9)* 
.03 
(-. 1 -. 1)* 
.17 















*Values in parentheses are (maximum decrease and maximum increase) 
Table 4 
Effect of Order of Administration of Gadolinium and Iodinated Contrast Agents on the Change in Serum Creatinine 
Serum Creatinine (mg/dLl 
No. of Gadolinium Contrast Iodinated Contrast 
Contrast Agent Patients Pre Post Delta Pre Post Delta 
Gadolinium first 30 2.06 2.04 -.02 1.97 2.28 .31 
Iodine first 34 2.34 2.22 -.12 2.01 2.39 .38 
Total 64 2.21 2.14 -.07 1.99 2.34 .35 
1). None of the remaining 1 10 patients had any clinically 
significant change in renal function or evidence of toxicity 
after gadolinium. Overall, there was a minimal decrease 
in the mean serum creatinine level after high-dose gad- 
olinium, as shown in Table 1 (P < .01). This observation 
of a negligible change in serum creatinine was also made 
for each of the three gadolinium compounds examined 
independently of the other compounds. This effect was 
not dose-dependent, as shown in Table 2. 
Sixty-four patients received both gadolinium and iodi- 
nated contrast on separate days. In these patients, there 
was a significant increase in serum creatinine after iodi- 
nated contrast compared with a negligible change after 
gadolinium contrast (P < .01; Table 3). This observation 
was also made with each of the three gadolinium com- 
pounds analyzed separately and was statistically signifi- 
cant for gadopentetate dimeglumine and gadodiamide. 
The lower serum creatinine levels measured in these pa- 
tients before iodinated contrast reflects the hydration and 
optimization of medical management performed before 
the iodinated contrast administration that was not per- 
formed before the MFU. 
Table 4 shows these data from the 64 patients who re- 
ceived both gadolinium and iodinated contrast, catego- 
rized according to the order in which the contrast ex- 
aminations were performed. Thirty patients received 
gadolinium first and with an interval between gadolinium 
and iodinated contrast ranging from 1 to 99 days (me- 
dian, 7 days). Thirty-four patients received iodinated con- 
trast first with an interval ranging from 1 to 598 days 
(median, 10 days). In eight patients, the interval was less 
than 2 days. Regardless of the order in which contrast 
agents were administered, there was a small decrease in 
serum creatinine after gadolinium and a substantial in- 
crease in serum creatinine after iodinated contrast. 
When the patients were further broken down into sub- 
groups who had pre-existing renal insufficiency with se- 
rum creatinine levels > 1.5 mg/dL, the change in serum 
creatinine levels was even larger with the iodinated con- 
trast, as expected (Table 5). The change with gadolinium 
was still negligible. For the patients with serum creati- 
nine levels in excess of 1.5 mg/dL, the incidence of con- 
trast-induced renal failure was 29% with iodinated 
contrast (nine patients), compared with 0% for the gad- 
olinium contrast agents. The effect of pre-existing renal 
insufficiency is further characterized in Table 6, which 
shows the patients’ change in serum creatinine, stratified 
according to their baseline serum creatinine. 
DISCUSSION 
Iodinated contrast-induced renal failure is estimated to 
occur in .15% to 2% of all patients undergoing contrast 
imaging studies, including arteriograms, CT, and intra- 
venous pyelography (16-19). Incidence is higher in pa- 
tients with renal insufficiency, dehydration, multiple 
myeloma, diabetes, and advanced age. In most cases, the 
renal failure is short-lived, typically requiring several 
days of hospitalization with an eventual return to base- 
line renal function. But an estimated 5% to 10% of these 
patients never fully recover their baseline renal function. 
These data in 64 patients who received both gadolin- 
ium and iodinated contrast demonstrate a significant in- 
crease in serum creatinine after iodinated contrast that 
was not seen with gadolinium contrast agents. In fact, 
there was a minimal decrease in serum creatinine after 
gadolinium contrast agents that presumably reflects the 
improved hydration from the saline given in combination 
with the gadolinium. This observation of less nephrotox- 
icity with gadolinium contrast agents was made using 
high doses of gadolinium (.2 to .4 mmol/kgl and in a pop- 
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Table 5 
Effect of Contrast on Serum Creatinine in Patients with Renal Insufficiency (Serum Creatinine > 1.5 mg/dl). 
Serum Creatinine (mg/dL) 
Mean f SD 
No. of (Minimum- Maximum) 
Contrast Agent Patients Pre Post Delta P Value Delta P Value 
Gadopentetate 10 3.64 ? 1.24 3.50 f 1.20 -.14 .22 
dimeglumine (2.3-5.7) (2.2-5.4) (-.7-.4)* .037 
Iodinated contrast 2.88 f .87 4.23 rtr 1.94 1.35 ,045 
(1.8-4.7) ( 1.8 - 7.8) (-.l-5.6)' 
Gadodiamide 17 3.52 f 1.89 3.31 f 1.87 -.21 .004 
Iodinated contrast 3.07 f 1.99 3.45 2 2.04 .38 .05 
(1.7-7.1) (1.5- 7.0) (-.7-. 1)* 
(.8-7.1) (.8-7.1) (-.3-2.9)* 
Gadoteridol 4 1.98 f .43 2.00 f .43 .02 .64 
(1.6- 2.5) ( 1.6- 2.6) (-. 1 -.1)* 
( 1.5 - 2.5) ( 1.8- 2.7) (.O- .5)* 
Iodinated contrast 2.05 t .42 2.30 f .42 .25 .13 
Total 
Gadolinium contrast 31 3.36 t 1.64 3.20 k 1.59 -.16 .004 
Iodinated contrast 2.88 ? 1.57 3.56 f 1.93 .68 .005 




(.8-7.1) (.8 - 7.8) (- .3- 5.6)' 
*Values in parentheses are maximum decrease and maximum increase. 
Table 6 
Stratification of Patients by Change in Creatinine after Gadolinium/after Iodine 
Baseline Serum No. of No Increase by Increase by Increase by 
Creatinine (mg/dL) Patients Decrease Change <.25 .25-.5 >.5 
<1.0 10 1 /2 5/3 4/5 o/o o/o 
1.0- 1.5 23 8/6 9/8 4/6 2/3 o/o 
>1.5-2.5 16 9/3 113 5/5 1 /3 0 / 2  
>2.5 15 11/1 213 1/1 1 /4 0/6 
ulation of patients as opposed to normal volunteers. 
Analysis of the subgroup of patients with underlying 
renal insufficiency showed these gadolinium contrast 
agents to also be less nephrotoxic than iodinated contrast 
in this group of patients who are at greatest risk of con- 
trast-induced renal failure. The absence of nephrotoxicity 
with gadolinium observed in this study did not require pre- 
hydration, mannitol, Lasix, or other special treatment, as 
is often performed with iodinated contrast administration. 
Failure to observe any increase in serum creatinine af- 
ter high-dose gadolinium contrast agents does not guar- 
antee that gadolinium chelates are absolutely free of 
nephrotoxicity, because serum creatinine is not the most 
sensitive indicator of renal injury. However, it does sug- 
gest that any nephrotoxicity that may be present is not 
clinically important at these gadolinium doses. The pos- 
sibility of other toxicity from gadolinium chelates must 
also be considered (21,221. Transient elevation of liver en- 
zymes has been reported in data from safety trials (23). 
There is also the theoretical possibility of heavy metal 
toxicity occurring if gadolinium dissociates from the che- 
lator. In clinical practice, however, these other toxicities 
have not been reported, even in patients with delayed ex- 
cretion of gadolinium caused by renal insufficiency (14). 
Dialysis should still be considered if a patient develops 
any signs of toxicity; it was not required in any of the 
patients in this study. 
Because the gadolinium chelates have similar phar- 
macokinetics and enhancement patterns as iodinated 
contrast, it is possible to reduce the risk of contrast-in- 
duced renal failure by substituting gadolinium-enhanced 
MRI examinations for iodinated contrast-enhanced CT 
scans and angiograms. Use of gadolinium in place of io- 
dinated contrast has also been reported in conventional 
angiography (24) and CT (25). The high atomic weight of 
gadolinium makes it comparably radiopaque as iodinated 
contrast (iodine atomic weight = 127, k-edge = 33 keV 
gadolinium atomic weight = 157, k-edge = 52 keV). The 
gadolinium chelates studied herein have a low incidence 
of adverse events and, in particular, severe allergic re- 
actions are extremely rare (26,271. This also contributes 
to increased safety of gadolinium, compared with iodi- 
nated contrast. 
The retrospective nature of this study introduced sev- 
eral biases that represent significant limitations. The 
population was limited to patients who were having daily 
serum creatinine measurements at the time of MFU. This 
heavily weighted the population toward inpatients and 
patients with underlying renal insufficiency. In general, 
inpatients tend to be sicker than outpatients. Limiting 
the study to patients who received high-dose gadolinium 
biased the study population toward patients with cardi- 
ovascular disease, because high-dose gadolinium is only 
used for MR angiography at our institution. Although 
these are significant biases, these data corroborate other 
reports on the absence of observable nephrotoxicity with 
these gadolinium contrast agents (3-14). Taken together, 
the argument for substituting gadolinium-enhanced MRI 
examinations for iodinated contrast-enhanced examina- 
tions to decrease the risk of nephrotoxicity is compelling. 
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